CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5 enrolled
Drug / intervention
Mablet (Magnesium-supplement) +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01113151
NCT01113151N/ACompleted
CompareCT.gov

Daily Magnesium-supplement With Mablet for Steroid-resistant, Severe Asthmatics

University of Aarhus·interventional·Posted Apr 29, 2010·Updated Sep 4, 2013

In Brief

A clinical study evaluating Mablet (Magnesium-supplement) and Placebo for Asthma. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that a daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease. The aim of this part of the project is to reveal possible beneficial effects of daily magnesium supplement for severe asthmatics, refractory to conventional treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesDenmark
CollaboratorsGunnar Kjems APS, GCP-unit at Aarhus University Hospital, Aarhus, Denmark, Aarhus University Hospital

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 29, 2010
Enrollment StartApr 1, 2011
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 16.2 years ago

Interventions

Mablet (Magnesium-supplement)dietary

3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS

Placeboother

3 placebo tablets daily for 12 weeks